Kyverna Therapeutics, Inc. — All Filings
151 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
424B4
424B5
8-A12B
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
FWP
S-1
S-1/A
S-3
S-8
SC 13D
SC 13G
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | OWNERSHIP DOCUMENT | 0001104659-24-024091 | Feb 14, 2024 | Feb 12, 2024 |
| 4 | 4 | 0000950170-24-015358 | Feb 14, 2024 | Feb 12, 2024 |
| SC 13G | SC 13G | 0001193125-24-036609 | Feb 14, 2024 | — |
| SEC STAFF LETTER | — | 9999999997-24-000276 | Feb 13, 2024 | — |
| 4 | 4 | 0000950170-24-014000 | Feb 12, 2024 | — |
| 8-K | 8-K | 0001193125-24-032161 | Feb 12, 2024 | — |
| S-8 | S-8 | 0001193125-24-028421 | Feb 8, 2024 | — |
| 424B4 | 424B4 | 0001193125-24-028334 | Feb 8, 2024 | — |
| CERT | — | 0001354457-24-000049 | Feb 8, 2024 | — |
| 3 | 3 | 0000950170-24-012524 | Feb 8, 2024 | Feb 7, 2024 |
| 3 | 3 | 0000950170-24-012491 | Feb 8, 2024 | Feb 7, 2024 |
| EFFECT | — | 9999999995-24-000343 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012489 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012488 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012486 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012484 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012483 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012482 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012481 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012476 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012475 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012474 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012473 | Feb 7, 2024 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-24-011799 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012469 | Feb 7, 2024 | — |
| 3 | 3 | 0000950170-24-012454 | Feb 7, 2024 | — |
| S-1/A | S-1/A | 0001193125-24-024683 | Feb 6, 2024 | — |
| CORRESP | — | 0001193125-24-024056 | Feb 5, 2024 | — |
| CORRESP | — | 0001193125-24-024040 | Feb 5, 2024 | — |
| 8-A12B | 8-A12B | 0001193125-24-024032 | Feb 5, 2024 | — |
| S-1/A | S-1/A | 0001193125-24-021237 | Feb 1, 2024 | — |
| CORRESP | — | 0001193125-24-015399 | Jan 25, 2024 | — |
| CORRESP | — | 0001193125-24-008616 | Jan 16, 2024 | — |
| S-1 | S-1 | 0001193125-24-008614 | Jan 16, 2024 | — |
| UPLOAD | — | 0000000000-24-000336 | Jan 10, 2024 | — |
| DRS/A | — | 0000950123-24-000056 | Jan 8, 2024 | — |
| DRSLTR | — | 0000950123-24-000057 | Jan 5, 2024 | — |
| UPLOAD | — | 0000000000-23-014149 | Dec 28, 2023 | — |
| SEC STAFF LETTER | — | 9999999997-23-004773 | Dec 15, 2023 | — |
| DRSLTR | — | 0000950123-23-011180 | Dec 13, 2023 | — |
| DRS/A | — | 0000950123-23-011179 | Dec 13, 2023 | — |
| UPLOAD | — | 0000000000-23-012756 | Nov 21, 2023 | — |
| DRSLTR | — | 0000950123-23-009835 | Nov 9, 2023 | — |
| DRS/A | — | 0000950123-23-009831 | Nov 9, 2023 | — |
| D | — | 0001994702-23-000001 | Nov 7, 2023 | — |
| UPLOAD | — | 0000000000-23-011959 | Nov 1, 2023 | — |
| DRS | — | 0000950123-23-008697 | Oct 5, 2023 | — |